Twist Bioscience Corp (TWST) FinancialsTWSTTwist Bioscience Corp

Twist Bioscience Corporation (TWST) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is NGS applications, accounting for 52.2% of total sales, equivalent to $61.80M. Another important revenue stream is DNA synthesis and protein solutions. Understanding this composition is critical for investors evaluating how TWST navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Twist Bioscience Corporation maintains a gross margin of 52.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -30.65%, while the net margin is -29.61%. These profitability ratios, combined with a Return on Equity (ROE) of -29.59%, provide a clear picture of how effectively TWST converts its operational activities into shareholder value.

In the context of the broader market, TWST competes directly with industry leaders such as PCVX and KYMR. With a market capitalization of $7.44B, it holds a significant position in the sector. When comparing efficiency, TWST's gross margin of 52.76% stands against PCVX's N/A and KYMR's 100.00%. Such benchmarking helps identify whether Twist Bioscience Corporation is trading at a premium or discount relative to its financial performance.

Twist Bioscience has shown increasing total revenue, with Q3 2026 revenue reported at $118.38 million, up from $99.01 million in Q4 2025. The gross margin has also improved, reaching 52.76% in Q3 2026, reflecting efficient cost management.